Tarsus Pharmaceuticals, Inc. TARS Product sales, net — Total revenues

Similar metrics at other companies

BCRXProduct sales, net — Total revenues

$151.4M+5.3%

TVTXTotal net product sales — Total Revenue

$124.49M+64.1%

MIRMProduct sales, net — Product sales, net

$159.88M+43.3%

SUPNNet product sales — Total revenues

$150.75M+6.2%

AUPHNet product sales — Revenue

$73.56M+22.7%

CRNXProduct revenue, net — Total Revenue

$10.31M—

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues?

Tarsus Pharmaceuticals, Inc. (TARS) reported product sales, net — total revenues of $145.39M in Q1 2026.

How has Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues changed year-over-year?

Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues increased by 85.6% year-over-year, from $78.34M to $145.39M.

What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues?

Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues has grown at a 453.6% compound annual growth rate (CAGR), from $14.73M to $451.36M.

What does product sales, net — total revenues mean?

This metric represents the total gross revenue generated from the sale of pharmaceutical products after accounting for variable considerations such as rebates, discounts, and returns. It serves as a primary indicator of market adoption and commercial success for the company's therapeutic portfolio. Growth in this figure reflects the effective penetration of the company's products within its target ophthalmic patient population.